InsiderTrades

Form 4 for DGX Quest Diagnostics

Accepted 2022-07-05 00:00:00 ET · period of report 2022-07-01 · accession 0001022079-22-000112 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-07-05 2022-07-01 DGX RING TIMOTHY M Dir M - OptEx $57.46 +2,000 24.9K +9% +$114.9K
D 2022-07-05 2022-07-01 DGX RING TIMOTHY M Dir S - Sale+OE $133.47 -2,000 23.9K -8% -$266.9K
D 2022-07-05 2022-07-01 DGX RING TIMOTHY M Dir A - Grant $134.74 +308 12.4K +3% +$41.5K
DM 2022-07-05 2022-07-01 DGX RING TIMOTHY M Dir M - OptEx $57.46 -2,000 0 -100% -$114.9K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-07-01 M A 990 $58.69 25,933 D — —
2 Common Common Stock 2022-07-01 M A 1,010 $56.25 24,943 D — —
3 Common Common Stock 2022-07-01 S D 2,000 $133.47 23,933 D — —
4 Derivative Phantom Stock Units 2022-07-01 A A 308 $134.74 12,355.27 D $0.00 · — to — 308 Common Stock (F3) Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. (F2) Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.
5 Derivative Stock Options (Right to Buy) 2022-07-01 M D 1,010 $56.25 149 D $56.25 · 2013-04-01 to 2023-04-01 1,010 Common Stock
6 Derivative Stock Options (Right to Buy) 2022-07-01 M D 990 $58.69 0 D $58.69 · 2013-01-02 to 2023-01-02 990 Common Stock